Cancer breakthroughs trigger big pharma interest in drugs and deals.
A new article from the Guardian about immunotherapies, featuring Datamonitor Healthcare analyst Colin White
Datamonitor Healthcare is proud to be featured in the Guardian’s fascinating new article on cancer immunotherapy. You can read a quick extract below, but make sure you click to read the full article – it’s not one you’d want to miss out on.
“The new generation of drugs hailed as a once-in-a-generation advance in treatment for cancer patients is also viewed as good news for the pharmaceutical industry – just when analysts had started to voice concerns that the pipeline of blockbuster treatments in development was starting to run dry.
Immunotherapy treatments, which use the body’s immune system to attack cancerous cells, could be as revolutionary as the arrival of chemotherapy was in the 1940s – and big pharma companies have been scrambling to get into a market that experts think could eventually be worth up to £26bn a year in sales.”
To read the full article from the Guardian, featuring Datamonitor Healthcare’s Lead Oncology Analyst Colin White, click here >>
[Extract taken from Cancer Breakthroughs Trigger Big Pharma Interest in Drugs and Deals by Jennifer Rankin, The Guardian]
You can find out more about Colin by reading his bio here >>
Or keep up to date by following him on twitter here >>